Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:24 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2507

Shown on this page

Current sort

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Cleveland Clinic

Stored official records

Open in full search

Conditions: Guillain-Barre Syndrome
Interventions: Tanruprubart; Drug
Lead sponsor: Annexon, Inc.; Industry
Eligibility: 8 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 18 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 29 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more

Conditions: Advanced Solid Tumors
Interventions: Cetuximab, JAB-23E73; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more

Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 90
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ocrelizumab, Remibrutinib oral treatment; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 45
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 40 more

Conditions: Moderately to Severely Active Crohns Disease
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 64
States / cities: Dothan, Alabama • Glendale, Arizona • Lancaster, California + 57 more

Conditions: Pressure Injury, Spinal Cord Injury
Interventions: CAPP-FIT implementation during maintenance phase, CAPP-FIT intervention with RA facilitation, Provider training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Long Beach, California • Palo Alto, California • Tampa, Florida + 5 more

Conditions: Parkinson Disease
Interventions: High intensity stationary cycling; Other
Lead sponsor: Jay Alberts; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Duarte, California • Sacramento, California • Tampa, Florida + 5 more

Conditions: Kidney Stone
Interventions: passive suction via conventional sheath, vacuum assisted sheath; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: GERD, Paraesophageal Hernia
Interventions: OviTex Mesh, Pledgeted sutures; Device · Other
Lead sponsor: David Krpata; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pain, Postoperative
Interventions: IV Magnesium Sulfate; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 14 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Clinical trials in Cleveland, Ohio

Filter and sort this location

Institutions in Cleveland

Stored official records

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

Care in Multiple Sclerosis (MS)

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic

Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis

Mesh Vs Pledgets for Repair of Paraesophageal Hernia

Magnesium as an Adjuvant Agent for Postoperative Pain